Why Cytokinetics’ Stock Price Soared in a Bad Market Day

Cytokinetics Positive Topline Results of CK-274
Cytokinetics (CYTK) announced positive topline results of Phase 2 clinical trial of CK-274 - an investigational cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

The results inform dose selection. They also support the progression of CK-274 to a planned Phase 3 registrational clinical trial, expected to start before . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.